- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Bioscience
PANEL: Life sciences will see radically different future
May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues
of venture capital, digital health innovations and research university entrepreneurship.
MorePanel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
IU medical school's push to launch startups bears fruit
April 13, 2013
J.K. WallThe Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity
the school has never seen before.
MoreHealth care startups hungry for funds
February 2, 2013
J.K. WallFrustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create
a dedicated funding stream that could total $30 million a year.
MoreZimmer's earnings slip, but beat expectations
January 31, 2013
IBJ StaffFourth-quarter profit fell 2 percent at Zimmer Holdings Inc. due to large accounting charges, but still beat the estimates
of Wall Street analysts.
MoreBioCrossroads seed fund makes first investments
January 10, 2013
Local startups Esanex Inc. and Algaeon Inc. have received $500,000 and $250,000, respectively, from Indiana Seed Fund II,
BioCrossroads' second fund to help fledgling life sciences companies.
MoreNico raises $6.5 million more from existing investors
December 4, 2012
J.K. WallIndianapolis-based Nico Corp. wants to use its new round of capital to develop brain surgery products to address diseases
that were often considered inoperable, such as metastatic brain cancer and intracerebral hemorrhages.
MoreBioCrossroads has stoked state's life sciences industry, but challenges remain
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
MoreDow Agro posts record fourth quarter profit
February 2, 2012
IBJ Staff and Associated PressThe Indianapolis-based unit of Dow Chemical Co. saw earnings grow to $142 million, a fourth-quarter record and double the
$72 million reported for the 2010 period.
MoreBioCrossroads seeds upstart medical device maker
October 20, 2011
Chris O'MalleyBioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive
developing an absorbable stent.
MoreEx-Dow Agro scientist makes plea in trade-secret case
September 15, 2011
Associated PressA former Indiana scientist has agreed to plead guilty to charges of illegally sending trade secrets worth $300 million to
China and Germany.
MoreMedical implant maker plans move from northern Indiana
August 4, 2011
Associated PressRochester Medical Implants plans to move operations from Rochester to Noblesville in October. The company has 28 employees.
MoreMore life sciences firms opt to launch products in Europe
July 30, 2011
Maria LaMagnaThe U.S. Food and Drug Administration's growing reputation for unpredictability is spurring some Indianapolis companies to
join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations
occurring in their backyards.
MoreIndiana life sciences leaders look toward the future
July 30, 2011
Chris O'MalleyFormer Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez
and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry
in Indiana to venture capital and Purdue's Discovery Park.
MoreTech district could boost Indianapolis' convention business
July 23, 2011
Scott OlsonThe Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
MoreLilly plans more investment in two-in-one drugs
June 28, 2011
J.K. WallIndianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act
like two medicines in one. Lilly plans to add more scientists to back the effort.
MoreAnson Group CEO thrives on helping clients work with FDA
June 11, 2011
Ann FinchColleen Hittle became CEO and sole owner of the Indianapolis-based pharmaceutical and medical device consulting firm in April.
MoreCity to roll out plan for 16th Street tech corridor
June 10, 2011
Francesca JaroszThe city of Indianapolis plans to announce a major initiative to turn a stretch of 16th Street northwest of downtown into
a hub for biotechnology and other high-tech companies.
MoreLife sciences logistics firm opens new tissue storage facility
May 27, 2011
J.K. WallBioStorage Technologies' $4.6 million facility, located near the Indianapolis International Airport, will be used to prepare,
store and transport tissue and blood samples.
MoreTax breaks approved for bioanalytical lab operator
April 7, 2011
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.'s request for a tax abatement
to build a laboratory at Purdue Research Park in Indianapolis.
MoreBioanalytical researcher seeking abatement for new lab
April 5, 2011
Scott OlsonAdvion, a provider of bioanalytical research and a subsidiary of Ithaca, N.Y.-based Advion BioSciences Inc., is expected to
open the 22,000-square-foot lab in mid-May with 49 employees, according to the company's application.
MoreScientists question claims in biotech letter
April 1, 2011
Associated PressThe widespread Internet posting of a letter by a retired Purdue University researcher who says he has linked genetically modified
corn and soybeans to crop diseases and to abortions and infertility in livestock has raised concern among scientists that
the public will believe his unsupported claim is true.
MoreMarcadia Biotech principals ponder next course
March 22, 2011
Chris O'MalleyMarcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
MoreResearch jobs could flow from Purdue quad
March 19, 2011
Marc D. AllanPurdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health
Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers
who might well have left the state for either coast.
MoreMolecules are moneymakers for software firm Indigo BioSystems
January 29, 2011
Chris O'MalleyEli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
MoreAprimo sale may usher in 'new wave' of tech deals
January 8, 2011
Chris O'MalleyObservers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not
only among IT firms, but also among biotech companies here.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.
For those who let this information strike a nerve, remember that this is still the America that allows the freedom to achieve dreams and goals. Should you really chastise those who are given a perk on a deal that is supported by the consumer (that is until they don't like the deal anymore due to envy) or should the dream of rewards for working be looked at a little closer? I say lets stick to the deal, go to work,earn our keep, shoot for dreams, change our jobs to have that dream or shut up about others achievements ..............while we are still afforded this liberty of America !
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.